Prognostic and Predictive Role of Body Composition in Metastatic Neuroendocrine Tumor Patients Treated with Everolimus: A Real-World Data Analysis.
NET
adipose tissue
body composition
everolimus
mTOR inhibitors
muscle tissue
neuroendocrine tumors
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
30 Jun 2022
30 Jun 2022
Historique:
received:
28
04
2022
revised:
17
06
2022
accepted:
23
06
2022
entrez:
9
7
2022
pubmed:
10
7
2022
medline:
10
7
2022
Statut:
epublish
Résumé
Neuroendocrine tumors (NETs) are rare neoplasms frequently characterized by an upregulation of the mammalian rapamycin targeting (mTOR) pathway resulting in uncontrolled cell proliferation. The mTOR pathway is also involved in skeletal muscle protein synthesis and in adipose tissue metabolism. Everolimus inhibits the mTOR pathway, resulting in blockade of cell growth and tumor progression. The aim of this study is to investigate the role of body composition indexes in patients with metastatic NETs treated with everolimus. The study population included 30 patients with well-differentiated (G1-G2), metastatic NETs treated with everolimus at the IRCCS Romagnolo Institute for the Study of Tumors (IRST) "Dino Amadori", Meldola (FC), Italy. The body composition indexes (skeletal muscle index [SMI] and adipose tissue indexes) were assessed by measuring on a computed tomography (CT) scan the cross-sectional area at L3 at baseline and at the first radiological assessment after the start of treatment. The body mass index (BMI) was assessed at baseline. The median progression-free survival (PFS) was 8.9 months (95% confidence interval [CI]: 3.4-13.7 months). The PFS stratified by tertiles was 3.2 months (95% CI: 0.9-10.1 months) in patients with low SMI (tertile 1), 14.2 months (95% CI: 2.3 months-not estimable [NE]) in patients with intermediate SMI (tertile 2), and 9.1 months (95% CI: 2.7 months-NE) in patients with high SMI (tertile 3) (
Identifiants
pubmed: 35805003
pii: cancers14133231
doi: 10.3390/cancers14133231
pmc: PMC9264955
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Cancers (Basel). 2021 Dec 27;14(1):
pubmed: 35008278
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
J Clin Oncol. 2010 Feb 20;28(6):1054-60
pubmed: 20085939
Mol Clin Oncol. 2016 Nov;5(5):641-646
pubmed: 27900103
Endocr Relat Cancer. 2010 Aug 16;17(3):823-33
pubmed: 20603394
Front Oncol. 2020 Apr 07;10:414
pubmed: 32318336
Ann N Y Acad Sci. 2000 May;904:437-48
pubmed: 10865787
Skelet Muscle. 2016 Jul 26;6:26
pubmed: 27462398
Cell Metab. 2013 Mar 5;17(3):456-62
pubmed: 23473038
J Clin Invest. 2012 Nov;122(11):4243-56
pubmed: 23041627
JAMA Oncol. 2017 Oct 01;3(10):1335-1342
pubmed: 28448665
Expert Opin Pharmacother. 2018 Jun;19(8):909-928
pubmed: 29757017
Cancer Lett. 2012 Jun 1;319(1):1-7
pubmed: 22261336
Curr Opin Endocrinol Diabetes Obes. 2015 Oct;22(5):347-52
pubmed: 26313896
Curr Med Chem. 2014 Apr;21(10):1255-67
pubmed: 24304284
Dev Cell. 2006 Dec;11(6):859-71
pubmed: 17141160
Trends Pharmacol Sci. 2016 Apr;37(4):303-317
pubmed: 26700098
Int J Mol Sci. 2018 Jul 13;19(7):
pubmed: 30011848
Nat Cell Biol. 2019 Apr;21(4):476-486
pubmed: 30858581
Neuroendocrinology. 2016;103(2):117-8
pubmed: 26731186
J Clin Invest. 2010 Aug;120(8):2858-66
pubmed: 20664172
Cancer Res. 2012 Feb 1;72(3):747-56
pubmed: 22158946
Cancer Cell. 2007 Jul;12(1):9-22
pubmed: 17613433
Nat Med. 2002 Feb;8(2):128-35
pubmed: 11821896
Endocr Relat Cancer. 2010 Jul 28;17(3):719-29
pubmed: 20554786
Curr Cancer Drug Targets. 2013 Mar;13(3):267-77
pubmed: 23297825
Endocrine. 2021 Feb;71(2):502-513
pubmed: 33052555
Cell. 2017 Mar 9;168(6):960-976
pubmed: 28283069
Front Physiol. 2017 Oct 17;8:788
pubmed: 29089899
J Clin Oncol. 2013 Apr 20;31(12):1539-47
pubmed: 23530101
Cancers (Basel). 2022 Jan 20;14(3):
pubmed: 35158788
Acta Physiol (Oxf). 2014 Mar;210(3):489-97
pubmed: 24393306
Front Endocrinol (Lausanne). 2021 Mar 18;12:649496
pubmed: 33815296
Expert Opin Ther Pat. 2021 Nov;31(11):965-975
pubmed: 34098816
World J Surg Oncol. 2020 Aug 28;18(1):230
pubmed: 32859211
Pancreas. 2020 Aug;49(7):863-881
pubmed: 32675783
J Cell Physiol. 2021 Jan;236(1):215-221
pubmed: 32557691
Eur J Endocrinol. 2014 Feb 01;170(2):R43-55
pubmed: 24154684
Lancet Oncol. 2008 Jul;9(7):629-35
pubmed: 18539529
Clin Cancer Res. 2012 Mar 15;18(6):1777-89
pubmed: 22422409
Trends Mol Med. 2007 Jun;13(6):252-9
pubmed: 17452018
Clin Genitourin Cancer. 2017 Jun;15(3):350-355
pubmed: 28216276
Cell Metab. 2008 Nov;8(5):411-24
pubmed: 19046572
Cell. 2014 Jan 16;156(1-2):20-44
pubmed: 24439368